Semaglutide – Kodiac biolabs

Plain-language summaryIntrigue 92 / 100

Semaglutide, sold as Ozempic and Wegovy, is the most prescribed GLP-1 receptor agonist. It improves blood sugar control and produces dramatic weight loss. The compound has a long half-life of about a week, supporting once-weekly injection. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

75/100

The reference compound for GLP-1 obesity pharmacology, with unexpectedly broad biology still generating serious primary research

Semaglutide isnt novel anymore. That matters for the score and we should be honest about it. But novelty isnt the whole story, and with this compound there is a lot of story.

The structural engineering is worth understanding on its own terms. Native GLP-1 has a plasma half-life measured in minutes. Novo Nordisk engineered a weekly peptide through two amino acid substitutions, Aib at position 8 to block DPP-4 cleavage and Arg34Lys to reduce renal clearance, plus a C18 fatty diacid chain that enables reversible albumin binding. Rybelsus then adds SNAC co-formulation to achieve meaningful oral bioavailability from a peptide that would otherwise be degraded in the gut. These are real formulation achievements, not incremental tweaks.

The mechanism question is more interesting than single GLP-1 receptor agonism suggests. GLP-1 receptors are expressed in hypothalamic appetite circuits, brainstem reward pathways, cardiac tissue, renal tubules, and CNS regions now under active investigation for neurodegeneration. The SELECT trial, 17,604 non-diabetic obese participants with a 20 percent MACE reduction, confirmed that what this compound does extends well beyond glucose metabolism. FLOW established meaningful renal protection in diabetic kidney disease. STEP-HFpEF produced a real signal in heart failure with preserved ejection fraction. The EVOKE trial in early Alzheimer’s disease is ongoing and represents serious investment in a serious hypothesis. The GLP-1 receptor turns out to be a busier signaling node than anyone anticipated in 2017.

Where does it stand today? Tirzepatide has taken the weight loss efficacy crown with 20-plus percent body weight reduction in the SURMOUNT program, and retatrutide’s triple agonism data is coming. The single versus dual versus triple agonist question is live and genuinely interesting research. Semaglutide is the reference point for all of it. You cant understand the modern incretin class without this compound, and that gives it real bench value even as newer agents move past it on novelty.

What we think: this is the compound that proved the GLP-1 obesity concept was real and scalable. Its evidence base is among the deepest in recent pharmaceutical history. Ongoing indication work in cardiology, nephrology, and neurology means it continues to generate primary research, not just citations. Its not as exciting as retatrutide and it wont win a novelty contest, but it defines what best-in-class looked like for several years and remains a critical probe for GLP-1 receptor biology that keeps expanding in directions the field did not anticipate. Researchers working in metabolic, cardiovascular, or neurodegenerative biology need a position on this compound.

Novelty: 57
Mechanism promise: 72
In-category differentiation: 78
Evidence quality: 90
Translational signal: 88
Research bench value: 70

Rationale Scores high on evidence and translational signal given the extensive multi-indication phase 3 trial base (SELECT, FLOW, STEP-HFpEF, EVOKE) but novelty is limited since single GLP-1 agonism is now the established baseline; its role as the class reference standard and ongoing indication expansion keep it out of mature-workhorse territory even as tirzepatide supersedes it on weight loss efficacy.

GLP-1 receptor agonist (long-acting)

A long-acting GLP-1 receptor agonist FDA-approved as Ozempic (T2DM) and Wegovy (obesity), with extended duration through albumin-binding and amino acid substitution.

Abstract

Semaglutide (Ozempic, Wegovy, Rybelsus; CAS 910463-68-2; molecular weight 4113.58) is a long-acting GLP-1 receptor agonist developed by Novo Nordisk and approved for type 2 diabetes (Ozempic, 2017; Rybelsus oral, 2019) and chronic weight management (Wegovy, 2021). The compound is structurally based on native GLP-1 with two amino acid substitutions (Aib at position 8 to resist DPP-4 cleavage; Arg34Lys) and a fatty acid chain (octadecanoic diacid) attached via a glutamic acid spacer that enables reversible albumin binding for extended plasma half-life (approximately 1 week). Mechanism is GLP-1 receptor agonism producing glucose-dependent insulin release, glucagon suppression, gastric emptying delay, and central satiety effects. The semaglutide STEP program demonstrated 14 to 18 percent weight loss over 68 weeks in obesity trials; cardiovascular outcomes trials demonstrated MACE reduction in T2DM. Approved doses titrate to 1 mg per week (Ozempic), 2.4 mg per week (Wegovy), or 14 mg per day (Rybelsus oral). Schedule status: prescription-only.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-082Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.